# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATIONDECISION SUMMARYASSAY AND INSTRUMENT

I Background Information:

A 510(k) Number K233655   
B Applicant Abbott Diabetes Care Inc.   
C Proprietary and Established Names Lingo Glucose System   
D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>SAF</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 862.1355 -Integrated ContinuousGlucose MonitoringSystem</td><td rowspan=1 colspan=1>CH - ClinicalChemistry</td></tr></table>

II Submission/Device Overview:

A Purpose for Submission: New device   
B Measurand: Glucose from interstitial fluid.   
C Type of Test: Quantitative, amperometric assay (Glucose Oxidase).

# III Intended Use/Indications for Use:

A Intended Use(s): See Indications for Use below.

# B Indication(s) for Use:

The Lingo Glucose System is an over-the-counter (OTC) integrated Continuous Glucose Monitor (iCGM) intended to continuously measure, record, analyze and display glucose values in people 18 years and older not on insulin. The Lingo Glucose System helps to detect euglycemic and dysglycemic glucose levels. The Lingo Glucose System may also help the user better understand how lifestyle and behavior modification, including diet and exercise, impact glucose excursion.

The user is not intended to take medical action based on the device output without consultation with a qualified healthcare professional.

# C Special Conditions for Use Statement(s):

OTC - Over The Counter

Do not use the Lingo Biosensor if you are on dialysis or critically ill. It is not known how different conditions or medications common to these populations may affect performance of the System.

Only apply the Lingo Biosensor to the back of the upper arm. If placed in other areas, the Lingo Biosensor may not function properly.

Taking more than $1 0 0 0 \mathrm { m g }$ of Vitamin C per day may falsely raise your Lingo Biosensor readings. Vitamin C can be found in supplements including multivitamins and cold remedies such as Airborne $\textsuperscript { \textregistered }$ and Emergen- $C \textsuperscript { \textregistered }$ . See your health care professional to understand how long Vitamin C is active in your body.

# D Special Instrument Requirements:

Not applicable

# IV Device/System Characteristics:

# A Device Description:

The Lingo Glucose System is a home use device that is intended to continuously measure the glucose in the interstitial fluid, calculate the glucose reading and make this value available to the user. The Lingo System can reliably and securely transmit glucose measurement data to authorized digitally connected devices. The system is not intended to be used in conjunction with insulin devices such as insulin pens and Automated Insulin Dosing (AID) systems. The Lingo Glucose System includes the Lingo Glucose Biosensor and the Lingo App.

# Lingo Biosensor

The Lingo Glucose Biosensor hardware and technology is based on the FDA-cleared FreeStyle Libre 2 (FSL2) sensor (K222447). The Biosensor is a single use disposable on-body Biosensor

that incorporates a subcutaneously implanted electrochemical glucose sensor and associated electronics. The Biosensor can be worn for up for 14 days and transmits data to the Lingo App via Bluetooth Low Energy (BLE).

# Lingo App (iOS)

The Lingo App is designed to work in conjunction with the Lingo Glucose Biosensor. The Lingo App, which is the primary display for the Lingo System, operates on an iOS-compatible mobile device and can be downloaded from the Apple App Store.

# B Principle of Operation:

The Lingo Glucose System uses an electrochemical sensor to monitor glucose levels in the interstitial fluid (ISF). The sensor is held in place with an adhesive pad and incorporates both the subcutaneously implanted sensor and associated electronics. The sensor uses a glucose oxidase enzyme to oxidize glucose and transfer electrons to an electrode, producing a current. The strength of the current is proportional to the amount of glucose present in the ISF. The system converts the electrical current signal to a glucose value (in $\mathrm { m g / d L }$ ) for display to the user on a display device.

# C Instrument Description Information:

1. Instrument Name: Lingo Glucose System

2. Specimen Identification: Not applicable

3. Specimen Sampling and Handling: Not applicable

4. Calibration: The sensor is factory calibrated and does not require calibration from the user/operator.

5. Quality Control:

Not applicable

This medical device product has functions subject to FDA premarket review as well as functions that are not subject to FDA premarket review. For this application, if the product has functions that are not subject to FDA premarket review, FDA assessed those functions only to the extent that they either could adversely impact the safety and effectiveness of the functions subject to FDA premarket review or they are included as a labeled positive impact that was considered in the assessment of the functions subject to FDA premarket review.

# V Substantial Equivalence Information:

A Predicate Device Name(s): FreeStyle Libre 2 Flash Glucose Monitoring System   
B Predicate 510(k) Number(s): K222447   
C Comparison with Predicate(s):   
• 21 CFR 862.1355 (integrated continuous glucose monitoring system (iCGM)) special controls   
• ISO14971- 2019-12 “Medical Devices-Application of Risk Management to Medical Devices” IEC 62304 -“Medical Device Software-Software Life Cycle Processes” IEC 60601-1-“Medical Electrical Equipment -Part 1: General Requirements for Basic Safety and Essential Performance” AAMI TIR69-“Risk Management of Radio-Frequency Wireless Coexistence for Medical Devices and Systems” AAMI TIR57: 2016- “Principles for medical device security – Risk management” IEC 60601-1-2-“Medical electrical equipment - Part 1-2: General requirements for basic safety and essential performance - Collateral Standard: Electromagnetic disturbances - Requirements and tests” ISO 15223-1-“Medical Device-Symbols to be used with Medical Device Labels, Labeling and Information to be Supplied-Part 1: General Requirements”

<table><tr><td rowspan=1 colspan=1>Device &amp; PredicateDevice(s):</td><td rowspan=1 colspan=1>K233655</td><td rowspan=1 colspan=1>K222447</td></tr><tr><td rowspan=1 colspan=1>Device Trade Name</td><td rowspan=1 colspan=1>Lingo Glucose System</td><td rowspan=1 colspan=1>FreeStyle Libre 2 FlashGlucose MonitoringSystem</td></tr><tr><td rowspan=1 colspan=1>General DeviceCharacteristic Similarities</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>Automatically measureglucose in bodily fluidscontinuously for aspecified period of time.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Principle of operation</td><td rowspan=1 colspan=1>Amperometricmeasurement of currentproportional to glucoseconcentration ininterstitial fluid viaglucose oxidasechemical reaction.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>General DeviceCharacteristic Differences</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Intended Use Population</td><td rowspan=1 colspan=1>Persons 18 years andolder not on insulin</td><td rowspan=1 colspan=1>Persons with diabetesage 2 years and older</td></tr><tr><td rowspan=1 colspan=1>Availability to user</td><td rowspan=1 colspan=1>Over the counter</td><td rowspan=1 colspan=1>Prescription use only</td></tr><tr><td rowspan=1 colspan=1>Glucose Measuring Range</td><td rowspan=1 colspan=1>55 to 200 mg/dL</td><td rowspan=1 colspan=1>40 to 400 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Device features to managediabetes</td><td rowspan=1 colspan=1>None</td><td rowspan=1 colspan=1>Alarms, glucose trendarrows, interoperability</td></tr><tr><td rowspan=1 colspan=1>Wear period</td><td rowspan=1 colspan=1>14 days</td><td rowspan=1 colspan=1>15 days</td></tr></table>

# VII Performance Characteristics (if/when applicable):

# A Analytical Performance:

iCGM performance was evaluated using leveraged clinical studies from the predicate as the sensor component is identical. A new statistical analysis was performed to account for the different age range (predicate device is 2 years and older; subject device is 18 years and older), the truncated glucose measuring range (predicate device is $4 0 - 4 0 0 \mathrm { m g / d L }$ ; subject device is $5 5 - 2 0 0 ~ \mathrm { m g / d L } )$ ) and the shortened wear period (predicate device is 15 days; subject device is 14 days).

# 1. Precision/Reproducibility:

iCGM performance was evaluated in clinical studies described below in section C(3). Subjects wore two sensors concurrently, one on the back of each upper arm, to evaluate device precision.

In the study for all users, the mean paired absolute relative difference (between the 2 concurrently worn devices) was $8 . 4 \%$ ; and the median coefficient of variation (median $\% C V )$ was $4 . 2 \%$ ; mean $\% \mathrm { C V }$ was $5 . 9 \%$ .

# Precision Analysis

<table><tr><td rowspan=1 colspan=1>Glucose Level(mg/dL)</td><td rowspan=1 colspan=1>MeanCoefficientof Variation(%)</td><td rowspan=1 colspan=1>PairedAbsoluteDifference(mg/dL)</td><td rowspan=1 colspan=1>PairedAbsoluteRelativeDifference (%)</td><td rowspan=1 colspan=1>Number ofPairedReadings</td><td rowspan=1 colspan=1>Number ofSubjects</td></tr><tr><td rowspan=1 colspan=1>All</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>9.2</td><td rowspan=1 colspan=1>8.4</td><td rowspan=1 colspan=1>14202</td><td rowspan=1 colspan=1>148</td></tr></table>

2. Linearity: See assay Reportable Range below.

3. Analytical Specificity/Interference: Previously established in K222447.

4. Assay Reportable Range: The reportable range for the Lingo Glucose Monitoring System is 55 to $2 0 0 \mathrm { m g / d L }$ .

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods): The storage shelf-life of 9 months at 36 to $8 2 ~ \mathrm { { ^ \circ F } }$ within the humidity range of $10 \% - 9 0 \%$ previously established for the predicate in K222447 is applicable to the subject device.

6. Detection Limit: Not applicable

7. Assay Cut-Off: Not applicable

8. Accuracy (Instrument): Not applicable

9. Carry-Over: Not applicable

# B Comparison Studies:

1. Method Comparison with Predicate Device: Not applicable. Accuracy is determined by comparing device values to an FDA cleared laboratory grade glucose measurement method.

2. Matrix Comparison: Not applicable. Interstitial fluid is the only indicated matrix.

# C Clinical Studies:

1. Clinical Sensitivity: Not applicable

2. Clinical Specificity:

Not applicable

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable):

The clinical data of the predicate FreeStyle Libre 2 Flash Glucose Monitoring System (K222447) was reanalyzed to support the Lingo Glucose System.

The accuracy performance was assessed in a single pivotal clinical study conducted in the United States at seven centers.

The study enrolled 150 adult subjects with diabetes. Subjects wore two sensors for up to 16 consecutive days following Sensor application and accuracy analysis is based on the first applied sensor to each subject only. Subjects took part in up to three ten-hour clinical sessions that took place during four distinct periods: Days 1 to 3; Days 5 to 7; Days 9 to 11, and Days 13 to 15. During each clinic session, each subject’s glucose was manipulated to observe data spanning the measuring range. Data from day 15 of wear are not considered in the following analyses.

Device accuracy was evaluated by comparing iCGM glucose values to glucose values from venous blood draws measured with an FDA-cleared laboratory grade comparator method (YSI 2300). Glucose values were obtained from the system and from the comparator at the same or similar time. Glucose values outside of the subject device measuring range are not included in the following analysis. Absolute differences in $\mathrm { m g / d L }$ of values compared to the comparator method were calculated for all values below $7 0 \mathrm { m g / d L }$ . For values of $7 0 \mathrm { m g / d L }$ and above, percentage differences compared to the comparator method were calculated.

Percent and Point Accuracy by iCGM Glucose Range   

<table><tr><td rowspan=1 colspan=1>iCGMGlucoseRange(mg/dL)</td><td rowspan=1 colspan=1>No.Pairs</td><td rowspan=1 colspan=1>No.Subjects</td><td rowspan=1 colspan=1>Within15 mg/dL(95% LB)</td><td rowspan=1 colspan=1>Within40 mg/dL(95% LB)</td><td rowspan=1 colspan=1>Within15%(95% LB)</td><td rowspan=1 colspan=1>Within40%(95% LB)</td><td rowspan=1 colspan=1>MeanBias(mg/dL)</td><td rowspan=1 colspan=1>MARD(%)</td></tr><tr><td rowspan=1 colspan=1>&lt; 70(55-69)</td><td rowspan=1 colspan=1>2765</td><td rowspan=1 colspan=1>128</td><td rowspan=1 colspan=1>91.5 (89.4)</td><td rowspan=1 colspan=1>99.6 (99.3)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>-4.0</td><td rowspan=1 colspan=1>9.9</td></tr><tr><td rowspan=1 colspan=1>70 - 180</td><td rowspan=1 colspan=1>7513</td><td rowspan=1 colspan=1>148</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>82.1 (79.7)</td><td rowspan=1 colspan=1>99.6 (99.4)</td><td rowspan=1 colspan=1>-6.3</td><td rowspan=1 colspan=1>9.7</td></tr><tr><td rowspan=1 colspan=1>&gt;180(181-200)</td><td rowspan=1 colspan=1>808</td><td rowspan=1 colspan=1>138</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>86.5 (83.0)</td><td rowspan=1 colspan=1>99.9 (99.4)</td><td rowspan=1 colspan=1>-9.0</td><td rowspan=1 colspan=1>8.1</td></tr></table>

Percent and Point Accuracy by Comparator Method (CM) Glucose Range   

<table><tr><td rowspan=1 colspan=1>CMGlucoseRange(mg/dL)</td><td rowspan=1 colspan=1>No.Pairs</td><td rowspan=1 colspan=1>No.Subjects</td><td rowspan=1 colspan=1>Within15 mg/dL(95% LB)</td><td rowspan=1 colspan=1>Within40 mg/dL(95% LB)</td><td rowspan=1 colspan=1>Within15%(95% LB)</td><td rowspan=1 colspan=1>Within40%(95% LB)</td><td rowspan=1 colspan=1>MeanBias(mg/dL)</td><td rowspan=1 colspan=1>MARD(%)</td></tr><tr><td rowspan=1 colspan=1>&lt; 70(55-69)</td><td rowspan=1 colspan=1>2386</td><td rowspan=1 colspan=1>120</td><td rowspan=1 colspan=1>96.9 (95.5)</td><td rowspan=1 colspan=1>99.9 (99.6)</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>8.9</td></tr><tr><td rowspan=1 colspan=1>70 - 180</td><td rowspan=1 colspan=1>7564</td><td rowspan=1 colspan=1>149</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>81.4 (79.0)</td><td rowspan=1 colspan=1>99.6 (99.5)</td><td rowspan=1 colspan=1>-5.8</td><td rowspan=1 colspan=1>9.7</td></tr><tr><td rowspan=1 colspan=1>&gt;180(181-200)</td><td rowspan=1 colspan=1>1136</td><td rowspan=1 colspan=1>135</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>77.5 (73.3)</td><td rowspan=1 colspan=1>99.4 (98.8)</td><td rowspan=1 colspan=1>-21.9</td><td rowspan=1 colspan=1>10.7</td></tr></table>

Percent of iCGM values within $2 0 \%$ of Comparator Glucose Values $( \mathbf { N = 1 4 9 } )$   

<table><tr><td rowspan=1 colspan=1>iCGM Glucose Range</td><td rowspan=1 colspan=1>Matched Pairs (n)</td><td rowspan=1 colspan=1>Percent within 20%(95% LCL)</td></tr><tr><td rowspan=1 colspan=1>55-200 mg/dL</td><td rowspan=1 colspan=1>11086</td><td rowspan=1 colspan=1>89.9 (88.0)</td></tr></table>

# Concurrence

Concurrence of iCGM values compared to the comparator method across the entire measuring range was also evaluated. iCGM glucose ranges of ${ < } 5 5$ , 55-70, 71-90, 91-120, 121-160, 161-200, and ${ > } 2 0 0 ~ \mathrm { m g / d L }$ were evaluated against the comparator glucose ranges and the percentages of iCGM values within those ranges were reported in the following tables.

Concurrence of iCGM and Comparator by iCGM Glucose Range   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2></td><td rowspan=1 colspan=5>Comparator Glucose Values (mg/dL)</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>iCGM(mg/)dL</td><td rowspan=1 colspan=1>&lt;55</td><td rowspan=1 colspan=1>55-70</td><td rowspan=1 colspan=1>71-90</td><td rowspan=1 colspan=1>91-120</td><td rowspan=1 colspan=1>121-160</td><td rowspan=1 colspan=1>161-200</td><td rowspan=1 colspan=1>&gt;200</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>&lt;55</td><td rowspan=1 colspan=1>39.5%</td><td rowspan=1 colspan=1>48.4%</td><td rowspan=1 colspan=1>9.9%</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.1%</td><td rowspan=1 colspan=1>0.1%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>706</td></tr><tr><td rowspan=1 colspan=1>55-70</td><td rowspan=1 colspan=1>8.4%</td><td rowspan=1 colspan=1>65.9%</td><td rowspan=1 colspan=1>23.4%</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>0.4%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>2913</td></tr><tr><td rowspan=1 colspan=1>71-90</td><td rowspan=1 colspan=1>0.4%</td><td rowspan=1 colspan=1>16.5%</td><td rowspan=1 colspan=1>52.5%</td><td rowspan=1 colspan=1>28.4%</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>0.1%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>1851</td></tr><tr><td rowspan=1 colspan=1>91-120</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>7.4%</td><td rowspan=1 colspan=1>62.7%</td><td rowspan=1 colspan=1>27.2%</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.1%</td><td rowspan=1 colspan=1>2200</td></tr><tr><td rowspan=1 colspan=1>121-160</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.2%</td><td rowspan=1 colspan=1>6.4%</td><td rowspan=1 colspan=1>71.8%</td><td rowspan=1 colspan=1>20.0%</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>2355</td></tr><tr><td rowspan=1 colspan=1>161-200</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.1%</td><td rowspan=1 colspan=1>9.8%</td><td rowspan=1 colspan=1>68.0%</td><td rowspan=1 colspan=1>22.1%</td><td rowspan=1 colspan=1>1767</td></tr><tr><td rowspan=1 colspan=1>&gt;200</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.1%</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>97.5%</td><td rowspan=1 colspan=1>7243</td></tr></table>

Concurrence of iCGM and Comparator by Comparator Glucose Range   

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=7>Comparator Glucose Values (mg/dL)</td></tr><tr><td rowspan=1 colspan=1>iCGM(mg/dL</td><td rowspan=1 colspan=1>&lt;55</td><td rowspan=1 colspan=1>55-70</td><td rowspan=1 colspan=1>71-90</td><td rowspan=1 colspan=1>91-120</td><td rowspan=1 colspan=1>121-160</td><td rowspan=1 colspan=1>161-200</td><td rowspan=1 colspan=1>&gt;200</td></tr><tr><td rowspan=1 colspan=1>&lt;55</td><td rowspan=1 colspan=1>52.6%</td><td rowspan=1 colspan=1>13.2%</td><td rowspan=1 colspan=1>3.7%</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.1%</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>55-70</td><td rowspan=1 colspan=1>46.0%</td><td rowspan=1 colspan=1>74.2%</td><td rowspan=1 colspan=1>36.1%</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>0.4%</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>71-90</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>11.8%</td><td rowspan=1 colspan=1>51.3%</td><td rowspan=1 colspan=1>24.7%</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.1%</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>91-120</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.7%</td><td rowspan=1 colspan=1>8.6%</td><td rowspan=1 colspan=1>64.9%</td><td rowspan=1 colspan=1>23.8%</td><td rowspan=1 colspan=1>2.0%</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>121-160</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>0.3%</td><td rowspan=1 colspan=1>7.1%</td><td rowspan=1 colspan=1>67.1%</td><td rowspan=1 colspan=1>25.0%</td><td rowspan=1 colspan=1>0.5%</td></tr><tr><td rowspan=1 colspan=1>161-200</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.1%</td><td rowspan=1 colspan=1>6.9%</td><td rowspan=1 colspan=1>63.6%</td><td rowspan=1 colspan=1>5.2%</td></tr><tr><td rowspan=1 colspan=1>&gt;200</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>0.2%</td><td rowspan=1 colspan=1>9.3%</td><td rowspan=1 colspan=1>94.3%</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>530</td><td rowspan=1 colspan=1>2586</td><td rowspan=1 colspan=1>1892</td><td rowspan=1 colspan=1>2125</td><td rowspan=1 colspan=1>2521</td><td rowspan=1 colspan=1>1887</td><td rowspan=1 colspan=1>7494</td></tr></table>

Trend accuracy describes the accuracy of the sensor during times of rapidly changing glucose and is characterized by slopes, such as from $> 2 \mathrm { m g / d L / m i n }$ to $< - 2 ~ \mathrm { m g / d L / m i n }$ . Trend accuracy was assessed by the concurrence rate of the glucose rate of change from the iCGM and the corresponding comparator values for each iCGM-comparator measurement pair.

Concurrence Analysis by Glucose Rate of Change   

<table><tr><td rowspan=2 colspan=1>iCGM Rate(mg/dL/min)</td><td rowspan=1 colspan=6>Comparator Rate (mg/dL/min)</td></tr><tr><td rowspan=1 colspan=1>&lt;-2</td><td rowspan=1 colspan=1>[-2, -1)</td><td rowspan=1 colspan=1>[-1, 0)</td><td rowspan=1 colspan=1>[0, 1]</td><td rowspan=1 colspan=1>(1, 2]</td><td rowspan=1 colspan=1>&gt;2</td></tr><tr><td rowspan=1 colspan=1>&lt;-2</td><td rowspan=1 colspan=1>41(48.2%)</td><td rowspan=1 colspan=1>61(10.5%)</td><td rowspan=1 colspan=1>28(0.5%)</td><td rowspan=1 colspan=1>5(0.1%)</td><td rowspan=1 colspan=1>2(0.2%)</td><td rowspan=1 colspan=1>1(0.2%)</td></tr><tr><td rowspan=1 colspan=1>-2 to -1</td><td rowspan=1 colspan=1>22(25.9%)</td><td rowspan=1 colspan=1>197(33.8%)</td><td rowspan=1 colspan=1>166(3.1%)</td><td rowspan=1 colspan=1>23(0.7%)</td><td rowspan=1 colspan=1>5(0.6%)</td><td rowspan=1 colspan=1>2(0.4%)</td></tr><tr><td rowspan=1 colspan=1>-1 to 0</td><td rowspan=1 colspan=1>18(21.2%)</td><td rowspan=1 colspan=1>280(48.1%)</td><td rowspan=1 colspan=1>4294(80.8%)</td><td rowspan=1 colspan=1>1261(37.8%)</td><td rowspan=1 colspan=1>101(11.2%)</td><td rowspan=1 colspan=1>52(10.4%)</td></tr><tr><td rowspan=1 colspan=1>0 to 1</td><td rowspan=1 colspan=1>4(4.7%)</td><td rowspan=1 colspan=1>43(7.4%)</td><td rowspan=1 colspan=1>807(15.2%)</td><td rowspan=1 colspan=1>1907(57.1%)</td><td rowspan=1 colspan=1>486(53.9%)</td><td rowspan=1 colspan=1>203(40.5%)</td></tr><tr><td rowspan=1 colspan=1>1 to 2</td><td rowspan=1 colspan=1>0(0%)</td><td rowspan=1 colspan=1>1(0.2%)</td><td rowspan=1 colspan=1>13(0.2%)</td><td rowspan=1 colspan=1>122(3.7%)</td><td rowspan=1 colspan=1>205(22.8%)</td><td rowspan=1 colspan=1>103(20.6%)</td></tr><tr><td rowspan=1 colspan=1>&gt;2</td><td rowspan=1 colspan=1>0(0%)</td><td rowspan=1 colspan=1>0(0%)</td><td rowspan=1 colspan=1>5(0.1%)</td><td rowspan=1 colspan=1>21(0.6%)</td><td rowspan=1 colspan=1>102(11.3%)</td><td rowspan=1 colspan=1>140(27.9%)</td></tr><tr><td rowspan=1 colspan=1>Number ofPairediCGM-Comparator(N)</td><td rowspan=1 colspan=1>85</td><td rowspan=1 colspan=1>582</td><td rowspan=1 colspan=1>5313</td><td rowspan=1 colspan=1>3339</td><td rowspan=1 colspan=1>901</td><td rowspan=1 colspan=1>501</td></tr></table>

Agreement when iCGM Reads “< 55 mg/dL” or “> 200 mg/dL”

The Lingo Glucose System reports glucose readings between 55 and $2 0 0 \mathrm { m g / d L }$ . When the system determines the sensor reading is below $5 5 \mathrm { m g / d L }$ , it displays $\mathrm { ^ { 6 6 } { < 5 5 \mathrm { m g / d L ^ { 3 } } } }$ on the mobile app. When the system determines the sensor reading is above $2 0 0 \mathrm { m g / d L }$ , it displays $\mathrm { ^ { 6 6 } { > } 2 0 0 \ m g / d L ^ { \mathrm { { > } } } }$ on the mobile app. Because the system does not display glucose values below $5 5 \mathrm { m g / d L }$ or above $2 0 0 \mathrm { m g / d L }$ , the comparisons to the actual blood glucose levels (as determined by the comparator method) when the iCGM value is classified as $\mathrm { ^ { 6 6 } { < 5 5 \mathrm { m g / d L ^ { 3 } } } }$ or $^ { \mathrm { ~ \sc ~ \sec ~ } } > 2 0 0 \mathrm { m g / d L } ^ { \mathrm { , , } }$ is evaluated separately, and the cumulative percentages of when the comparator values were less than certain glucose values (for $\mathrm { ^ { 6 6 } { < 5 5 \mathrm { m g / d L ^ { 3 3 } } } }$ ) and when comparator values were greater than certain values (for $\mathrm { \Omega ^ { 6 5 } 2 0 0 m g / d L ^ { 5 5 } }$ ) are presented in the tables below.

Distribution of Comparator for iCGM Readings “< 55 mg/dL”   

<table><tr><td rowspan=2 colspan=1>iCGMReadings</td><td rowspan=2 colspan=1>CGM-ComparatorPairs</td><td rowspan=1 colspan=4>Comparator (mg/dL)</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>&lt;70</td><td rowspan=1 colspan=1>&lt;90</td><td rowspan=1 colspan=1>&lt;120</td><td rowspan=1 colspan=1>≥120</td></tr><tr><td rowspan=2 colspan=1>&lt;55mg/dL</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>621</td><td rowspan=1 colspan=1>691</td><td rowspan=1 colspan=1>704</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>706</td></tr><tr><td rowspan=1 colspan=1>Cumulative%</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>97.9</td><td rowspan=1 colspan=1>99.7</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1></td></tr></table>

Distribution of Comparator for iCGM Readings $\mathbf { \hat { \mu } } ^ { 6 6 } > 2 \mathbf { 0 0 } \mathbf { m g } / \mathbf { d L } ^ { 3 }$   

<table><tr><td rowspan=2 colspan=1>iCGMReadings</td><td rowspan=2 colspan=1>CGM-ComparatorPairs</td><td rowspan=1 colspan=6>Comparator (mg/dL)</td><td rowspan=2 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>&gt;180</td><td rowspan=1 colspan=1>&gt;150</td><td rowspan=1 colspan=1>&gt;120</td><td rowspan=1 colspan=1>&gt;90</td><td rowspan=1 colspan=1>&gt;70</td><td rowspan=1 colspan=1>≤70</td></tr><tr><td rowspan=2 colspan=1>&gt;200mg/dL</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>7226</td><td rowspan=1 colspan=1>7241</td><td rowspan=1 colspan=1>7243</td><td rowspan=1 colspan=1>7243</td><td rowspan=1 colspan=1>7243</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>7243</td></tr><tr><td rowspan=1 colspan=1>Cumulative%</td><td rowspan=1 colspan=1>99.8</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>→</td></tr></table>

# Sensor Stability

Sensor stability describes the performance of the sensor over the sensor lifetime. Sensors can be worn for up to 14 days. Performance was estimated by calculating the mean of the absolute relative differences between iCGM and comparator measurement and percentage of device readings within $1 5 \mathrm { m g / d L }$ or $1 5 \%$ $( 1 5 / 1 5 \% )$ , $2 0 \mathrm { m g / d L }$ or $20 \%$ $( 2 0 / 2 0 \% )$ and 40 $\mathrm { m g / d L }$ or $40 \%$ $( 4 0 / 4 0 \% )$ of the comparator values during the beginning, early middle, late middle, and end of the wear period. These times were defined as follows:

Beginning (Days 1, 2 or 3) • Early Middle (Days 5, 6 or 7), • Late Middle (Days 9, 10 or 11), and End (Days 13 or 14).

The mean absolute relative difference (MARD) and agreement rates with the comparator method were evaluated over 14 day life of the sensor.

Accuracy of iCGM vs Comparator by Wear Period   

<table><tr><td rowspan=1 colspan=1>Wear Period</td><td rowspan=1 colspan=1>No. Pairs</td><td rowspan=1 colspan=1>MARD (%)</td><td rowspan=1 colspan=1>Within±15% /±15mg/dL</td><td rowspan=1 colspan=1>Within±20% /±20mg/dL</td><td rowspan=1 colspan=1>Within±40% /±40mg/dL</td></tr><tr><td rowspan=1 colspan=1>Beginningdays (1-3)</td><td rowspan=1 colspan=1>3281</td><td rowspan=1 colspan=1>11.5</td><td rowspan=1 colspan=1>78.1</td><td rowspan=1 colspan=1>86.3</td><td rowspan=1 colspan=1>98.8</td></tr><tr><td rowspan=1 colspan=1>Early Middledays (5-7)</td><td rowspan=1 colspan=1>2896</td><td rowspan=1 colspan=1>8.5</td><td rowspan=1 colspan=1>87.0</td><td rowspan=1 colspan=1>93.9</td><td rowspan=1 colspan=1>99.7</td></tr><tr><td rowspan=1 colspan=1>Late Middledays (9-11)</td><td rowspan=1 colspan=1>2927</td><td rowspan=1 colspan=1>8.8</td><td rowspan=1 colspan=1>86.6</td><td rowspan=1 colspan=1>93.4</td><td rowspan=1 colspan=1>99.2</td></tr><tr><td rowspan=1 colspan=1>Enddays (13-14)</td><td rowspan=1 colspan=1>1982</td><td rowspan=1 colspan=1>9.2</td><td rowspan=1 colspan=1>87.2</td><td rowspan=1 colspan=1>92.3</td><td rowspan=1 colspan=1>99.3</td></tr></table>

The sensor can be worn for up to 14 days. 151 Sensors were evaluated on the adult subjects to determine how many days of readings each Sensor provided.

Of the 151 sensors, $7 7 . 1 \%$ lasted until the final day of use. Some sensors were excluded from the analysis. For example, 4 sensors were intentionally removed due to subjects withdrawing or dropped out from the study early, one of which occurred during day 1 of the study. Of the sensors that did not last until the final day of use, 4 sensors $( 2 . 6 \% )$ had “early sensor shutoff” where the sensor algorithm detected that the sensor did not function as intended and automatically ended a sensor session. The Kaplan-Meier method was used to estimate how long a sensor will work over the wear duration.

Sensor Survival Rate Over Wear Duration   

<table><tr><td rowspan=1 colspan=1>Day of Wear</td><td rowspan=1 colspan=1>No. of Sensors</td><td rowspan=1 colspan=1>Survival Rate (%)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>100.0</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>149</td><td rowspan=1 colspan=1>99.3</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>147</td><td rowspan=1 colspan=1>98.0</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>142</td><td rowspan=1 colspan=1>94.7</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>139</td><td rowspan=1 colspan=1>93.3</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>138</td><td rowspan=1 colspan=1>92.7</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>131</td><td rowspan=1 colspan=1>88.0</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>129</td><td rowspan=1 colspan=1>86.6</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>127</td><td rowspan=1 colspan=1>85.3</td></tr><tr><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>83.9</td></tr><tr><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>122</td><td rowspan=1 colspan=1>81.9</td></tr><tr><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1>79.9</td></tr><tr><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>111</td><td rowspan=1 colspan=1>77.1</td></tr></table>

# Glucose Reading Availability

The system is designed to show a Sensor glucose reading after each scan that is performed throughout the wear period after the start-up time. As such, the capture rate characterizes the reliability of the communication between components of the system.

Glucose Reading Capture Rate Over Wear Duration   

<table><tr><td rowspan=1 colspan=1>Day of Wear</td><td rowspan=1 colspan=1>No. of Sensors</td><td rowspan=1 colspan=1>Capture Rate (%)</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>146</td><td rowspan=1 colspan=1>96.4</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>146</td><td rowspan=1 colspan=1>97.4</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>146</td><td rowspan=1 colspan=1>97.7</td></tr><tr><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>142</td><td rowspan=1 colspan=1>97.8</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>143</td><td rowspan=1 colspan=1>97.9</td></tr><tr><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>141</td><td rowspan=1 colspan=1>97.9</td></tr><tr><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>136</td><td rowspan=1 colspan=1>98.1</td></tr><tr><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>135</td><td rowspan=1 colspan=1>98.1</td></tr><tr><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>130</td><td rowspan=1 colspan=1>98.2</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>127</td><td rowspan=1 colspan=1>98.3</td></tr><tr><td rowspan=1 colspan=1>11</td><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>98.2</td></tr><tr><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>123</td><td rowspan=1 colspan=1>98.2</td></tr><tr><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>118</td><td rowspan=1 colspan=1>98.2</td></tr><tr><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>116</td><td rowspan=1 colspan=1>98.2</td></tr></table>

# D Clinical Cut-Off:

Not applicable.

# E Expected Values/Reference Range:

Not applicable

# F Other Supportive Instrument Performance Characteristics Data:

The following supportive performance characteristics were established through nonclinical testing of the predicate device and are applicable to the Lingo Glucose System:

• Biocompatibility • Sterilization Validation • Shelf Life

• Electrical and Mechanical Performance   
• Operating Environmental Conditions Testing   
• Wireless Coexistence   
• Electrical Safety and Electromagnetic Compatibility   
• Packaging Validation Interoperability

The following performance characteristics were verified or validated through studies conducted on the subject device, the Lingo Glucose System:

# Electromagnetic Compatibility

Electromagnetic compatibility (EMC) testing was performed for the Lingo Glucose System to verify that the system is able to withstand the electromagnetic interference and emissions in compliance with IEC 60601-1-2 and IEC CISPR 11. Wireless coexistence testing was performed to confirm that the sensor remains functional and perform within acceptable limits while in the presence of common radiating electronic devices in accordance with FDA Guidance “Radio Frequency Wireless Technology in Medical Devices.” The subject device underwent coexistence testing consistent with AAMI TIR69 and ANSI C63.27 and included test challenges from inband interference sources defined in ANSI C63.27 as well as other expected wireless interference sources from the intended use environment. The Lingo Glucose System also successfully demonstrated compliance with Federal Communication Commission (FCC) Regulations Part 15.225 and Part 15.247, and Federal Aviation Administration (FAA) Advisory Circular RTCA DO-160.

# Mechanical Engineering

The subject device underwent performance testing at the system level as well as on individual components of the Sensor Applicator. The test results showed that mechanical, electrical, and functional testing all met the acceptance criteria.

# Software Verification and Validation

Software verification and validation testing was conducted in accordance with established specifications and IEC 62304 and documentation was provided as recommended by FDA Guidance “Content of Premarket Submissions for Device Software Functions,” issued June 14, 2023. Results of executed protocols met the acceptance criteria and therefore support that the sensor’s embedded software and the Lingo App software are acceptable for its intended use.

# Cybersecurity

Abbott has provided cybersecurity risk management documentation for the System that includes analysis of confidentiality, integrity, and availability for data, information and software related to the System accordance with FDA Guidance “Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions,” issued September 27, 2023. For each identified threat and vulnerability risk event scenario, risk assessment of impact to confidentiality integrity, and availability was performed and documented within the cybersecurity risk management documentation. Appropriate risk mitigation controls have been implemented and tested.

# Human Factors

The user interface of the Lingo Glucose System has been found to support that the device is substantially equivalent to the predicate device for the intended users, uses, and use environments.

# VIII Proposed Labeling:

The labeling supports the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.